Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating zoledronic acid to prevent or delay bone metastasis in stage IIIA/IIIB non-small cell lung cancer has completed, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small-Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2011-07-19